Case Study B - Liquid Biopsy

X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood.

The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially available blood test as early as 2023.

• Project spearheaded by Singapore’s national Diagnostics Development (DxD) Hub
• Clinical trial introducing X-ZELL as an additional diagnostic tool
• Pilot study showed X-ZELL more than 70 per cent reduction in unnecessary biopsies